Bioreductive activation of quinones: A mixed blessing
- 66 Downloads
Quinones can be metabolized by various routes: substitution or reductive addition with nucleophilic compounds (mainly glutathione and protein thiol groups), one-electron reduction (mainly by NADPH: cytochrome P-450 reductase) and two-electron reduction (by D,T-diaphorase). During reduction semiquinone radicals and hydroquinones are formed, which can transfer electrons to molecular oxygen, resulting in the formation of reactive oxygen intermediates and back-formation of the parent quinone (redox cycling). Reaction of semiquinones and reactive oxygen intermediates with DNA and other macromolecules can lead to acute cytotoxicity and/or to mutagenicity and carcinogenicity. The enhanced DNA-alkylating properties of certain hydroquinones are exploited in the bioreductive alkylating quinones. Acute cytotoxicity of quinones appears to be related to glutathione depletion and to interaction with mitochondria and subsequent disturbance of cellular energy homoeostasis and calcium homoeostasis. These effects can to a certain extent be predicted from the electron-withdrawing and electron-donating effects of the substituents on the quinone nucleus of the molecule. Prediction of cytostatic potential remains much more complicated, because reduction of the quinones and the reactivity of the reduction products with DNA are modulated by the prevailing oxygen tension and by the prevalence of reducing enzymes in tumour cells.
KeywordsAlkylation Antineoplastic agents Biochemistry Cytotoxicity Oxidation-reduction Quinones
Unable to display preview. Download preview PDF.
- 1.Thomson RA. Distribution of naturally occurring quinones. Pharm Weekbl [Sci] 1991;13:70–3.Google Scholar
- 4.Redegeld FAM. Hepatic and renal toxicity of xenobiotics: the role of metabolism and transport [Dissertation]. Utrecht: University of Utrecht, 1989.Google Scholar
- 9.George CF, Shand DG, Renwick AG, eds. Presystemic drug elimination. London: Butterworth, 1981.Google Scholar
- 10.Koster AS, Richter E, Lauterbach F, Hartmann F, eds. Intestinal metabolism of xenobiotics. Stuttgart: Gustav Fischer Verlag, 1989. (Eichelbaum FM, Forth W, Meyer U, Van Zwieten PA, eds. Progress in pharmacology and clinical pharmacology; vol. 7. No. 2.)Google Scholar
- 11.Talalay P, De Long MJ, Prochaska HJ. Molecular mechanisms in protection against carcinogenesis. In: Cory JG, Szentivanyi A, eds. Cancer biology and therapeutics. New York: Plenum Press, 1987:197–216.Google Scholar
- 15.Lepoittevin J-P, Benezra C. Allergic contact dermatitis caused by naturally occurring quinones. Pharm Weekbl [Sci] 1991;13:119–22.Google Scholar
- 21.Richter C, Frei B. Ca2+ release from mitochondria induced by prooxidants. Free Rad Biol Med 1988;84:363–75.Google Scholar
- 26.Kennedy KA. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Design 1987;2:181–94.Google Scholar
- 27.Lusthof KJ, Groothuis-Pielage IL, Decuyper J, et al. Potential anti-tumour 2,5-bis(1-aziridinyl)-1,4-benzoquinones: relationship between cytotoxicity against DNA-repair deficientE. coli, inactivation of bacteriophage M13mp19, andin vitro andin vivo anti-tumour activity. Anticancer Drug Design 1988;3:147–55.Google Scholar